WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018008017) CIRCULATING MICRORNAS AS BIOMARKERS FOR THERAPY IN NEUROMYELITIS OPTICA (NMO) AND MULTIPLE SCLEROSIS (MS)
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/008017    International Application No.:    PCT/IL2017/050741
Publication Date: 11.01.2018 International Filing Date: 03.07.2017
IPC:
C12Q 1/68 (2006.01), G01N 33/564 (2006.01)
Applicants: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. [IL/IL]; P.O. Box 12000 9112001 Jerusalem (IL)
Inventors: LAVON BEN MOSHE, Iris; (IL).
VAKNIN-DEMBINSKY, Adi; (IL)
Agent: WEBB, Cynthia; Webb & CO. P.O. BOX 2189 7612101 REHOVOT (IL).
WEBB, Cynthia; (IL).
BARZAM, Maty; (IL).
BOGIN, Liora; (IL).
BURSTEIN, Tal; (IL).
FINAROV, Igal; (IL).
GANOR, Sharon; (IL).
HORNIK, Vered; (IL).
NOAH, Eran; (IL).
POTASH, Shay; (IL).
SCHICKLER, Hedva; (IL).
SCHVARTZ, Iris; (IL).
SILVERMAN, Eran; (IL).
TRAVITSKY, Nina; (IL).
WEBB, Yael; (IL).
ZIPOR, Gadi; (IL)
Priority Data:
62/358,015 03.07.2016 US
Title (EN) CIRCULATING MICRORNAS AS BIOMARKERS FOR THERAPY IN NEUROMYELITIS OPTICA (NMO) AND MULTIPLE SCLEROSIS (MS)
(FR) MICRO-ARN CIRCULANTS EN TANT QUE BIOMARQUEURS POUR UNE THÉRAPIE DANS LA NEUROMYÉLITE OPTIQUE (NMO) ET DE LA SCLÉROSE EN PLAQUES (SEP)
Abstract: front page image
(EN)The invention relates to circulating micro RNAs as biomarkers in Neuromyelitis Optica (NMO) and/or multiple sclerosis (MS). The invention further relates to circulating mi RNA profile for the prediction of responsiveness to treatment, such as, rituximab, of subjects afflicted with NMO and/or MS.
(FR)L'invention concerne des micro-ARN circulants en tant que biomarqueurs dans la neuromyélite optique (NMO) et/ou la sclérose en plaques (SEP). L'invention concerne en outre un profil de miARN circulants pour la prédiction de la sensibilité à un traitement, tel que le rituximab, de sujets souffrant de NMO et/ou de SEP.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)